IP Verse

Pharmaceutical Compositions For The Treatment Of Cftr Mediated Diseases

Patent No. EP2914248 (titled "Pharmaceutical Compositions For The Treatment Of Cftr Mediated Diseases") was filed by Vertex Pharmaceuticals Incorporated on Nov 1, 2013. The application was issued on Oct 18, 2023.

Patent Summary

Combination tablet therapy for treating cystic fibrosis using a specific ratio of two drugs, 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2). The tablet contains 100-200 mg Compound 1 Form I and 125 mg amorphous Compound 2. This combination provides balanced CFTR potentiation and correction for improved CFTR function in cystic fibrosis patients.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKJun 4, 2019TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2914248

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP13792149A
Filing Date
Nov 1, 2013
Status
Patent Maintained As Amended
Sep 15, 2023
Publication Date
Oct 18, 2023
External Links
Slate, Register , Google Patents